ViroPharma stock closed
Since then, some analysts say, it has become unclear whether the buyout will happen. "A deal would make sense, but it's still speculative," said
Eight years ago, ViroPharma was the comeback kid.
After federal regulators in 2002 rejected a medicine the company was developing that attacked the common-cold virus -- touted by some media as a potential cure -- ViroPharma changed its focus from early-stage research to later-stage products, moved to a smaller building, revamped its management team, and reduced debt.
The company also broadened its mission from antiviral medicines to include infectious diseases.
ViroPharma, which has 410 employees, 260 of them in
Vancocin treats the sometimes-deadly, hospital-acquired infection caused by a bacterium, Clostridium difficile. The drug had sales of about
Now, ViroPharma, with a
"There's certainly room for Cinryze to grow," Felt said, adding: "The company did a pretty good job of replacing the Vancocin revenue stream with Cinryze."
An experimental drug, Maribavir, is being tested to treat infections in bone-marrow and organ-transplant patients.
"The value of ViroPharma franchises could be diminished should they lose the protection of key patents, or should generic challengers take more share than we currently estimate,"
Neither ViroPharma chief executive officer
ViroPharma was formed in 1994 by
"Our story is a typical biotech story," former ViroPharma CEO
(c)2013 The Philadelphia Inquirer
Visit The Philadelphia Inquirer at www.philly.com
Distributed by MCT Information Services